Let’s start with the number that broke the stock: a $92.1 million net loss in Q1 2026. A year ago, same quarter, the company was profitable. That’s not a small swing.

Hims & Hers posted Q1 revenue of $608.1 million, up from $586 million a year earlier — but flipped from a $49.5M profit to a $92.1M net loss, or $(0.40) per diluted share versus $0.20 last year. That’s the headline. But the headline is also, to some degree, misleading — and that’s where it gets interesting.

The Restructuring Story

Results were pressured by $33.5 million in non-recurring restructuring and related charges tied to a U.S. weight-loss offering shift, plus $17.6 million of fair value losses on liabilities and $9.7 million on equity securities. So the loss isn’t purely operational — it’s partially the cost of unwinding a business model that worked really, really well, until regulators decided it didn’t.

Here’s the context. Hims built a massive chunk of its growth story on compounded semaglutide — cheaper, copycat versions of GLP-1 weight-loss drugs like Ozempic and Wegovy. The GLP-1 offering generated more than $225 million in revenue for the company in 2024. That’s not a side hustle. That was the engine.

Compounded drugs can be mass-produced when brand-name treatments are in shortage — but the FDA announced in February 2025 that ongoing supply issues had been resolved. That killed the legal justification for mass compounding. The company has since been pivoting away from copycat weight-loss medications and toward partnerships with pharmaceutical manufacturers.

Slight tangent, but it matters: In March, Novo Nordisk dropped its patent infringement lawsuit against the telehealth provider, and Hims & Hers announced a collaboration with Novo Nordisk, saying it would provide GLP-1 customers with access to a broad assortment of FDA-approved medications. A legal settlement that turns into a distribution deal is actually a decent outcome. But that transition doesn’t come free.

What the market reacted to wasn’t just the loss — it was the miss. Analysts had forecast the company would earn a tiny $0.01 per share profit on sales of $616.5 million. Instead, Hims & Hers lost $0.40 per share, and revenue came in at only $608 million. Missing on both lines in the same quarter, after a year of volatile sentiment around the stock, was enough to hit the eject button for a lot of holders.

HIMS stock sank 15% in premarket. By after-hours, shares were down roughly 9.4% to around $26.40, versus a 52-week trading range of $13.74 to $70.43. That range alone tells you everything about the volatility this name carries.

The Part People Are Skipping

GAAP losses are real, but they don’t always tell the full operational story. The company still generated $89.4 million in operating cash flow and ended the quarter with $222.3 million in cash and $528.6 million in short-term investments. That’s not a company bleeding out — that’s a company absorbing a painful one-time transition while keeping the lights on. There’s a difference.

Sales grew only 4% in the quarter, despite subscriber growth of 9% — which raises a fair question: are more customers actually spending less? That’s the kind of unit economics problem that doesn’t show up in the revenue line until it becomes unavoidable.

Management, for its part, is leaning hard into the long-term vision. The CFO stated the company expects growth to accelerate and expressed high conviction in 2030 targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. Whether you believe that depends entirely on how you think the branded GLP-1 partnership model plays out — and whether Hims can hold onto customers who were drawn in by cheap compounded drugs.

There’s also the expansion angle. Hims & Hers closed the $153 million YourBio acquisition and outlined a planned Eucalyptus purchase for up to $1.15 billion. Bold spending at a moment when the core business is under pressure. Some will call that conviction. Others will call it distraction.

Here’s where I’m at: this isn’t a broken business. But it’s also not a clean story right now. The GLP-1 pivot is a real strategic shift that carries real transition costs, and the market is making them pay for every dollar of that uncertainty. The company raised its 2026 revenue guidance to $2.8–$3.0 billion, but margins are under pressure due to increased operating expenses and restructuring costs.

The bull case requires believing that branded GLP-1 partnerships hold, that subscriber growth re-accelerates spending, and that the acquisitions add more than complexity. That’s a lot of moving pieces to trust at once.

What happens next quarter will matter more than this one.